Replies to post #369107 on Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

"Ceo should try harder to generate excitement and new interest. What about pro ball Pr firm, is ceo talking to squawk box?"

I suspect he only talks to himself,and likely doesn't answer.

Clearly, there is a lack of understanding regarding the "politics" of therapy development and granting of EUA..."IN THE AGE OF COVID-19" Your suggestion at this point in the game...(IMO ) suicide for Brilacidin and IPIX.

Leo has and is making all of the right moves from a regulatory review perspective..."FOLLOWING" FDA "guidance" regarding not "self-promoting" and likely clearance of all public statements before made.

IMO it is more important that he stay the course... than follow emotional urgings from some investors for Leo to promote for pennies. He has been around long enough to know... it's the Dollars, not the few pennies that count. You don't get to the dollars if you ruffle the feathers of the regulatory authorities...(See C*CD)

It is very clear (or should be) that Brilacidin's success against the Covid-19 indication will be revealed relatively shortly...again, IPIX is at the mercy of the CRO's chosen E.U. and U.S. labs and how quickly they can produce the results...but the "conclusion" of the trials...came faster than thought by some.

Brilacidin IS A FRANCHISE...

But is should be noted... we might be getting a Trifeca by or around or shortly after Labor Day... Brilacidin 1. Receiving EUA for Covid-19 (after IMO stellar Clinical Trial results) 2. OM Phase III announcment and commencement, and 3. Commencement of UP/UPS Clinical Trials by Licensee

Besides the Brilacidin/Covid-19 (Fast Track Designation) and concluded Clinical Trials...ALL the subsequent Independent Lab activity beyond Covid-19 cited in the last PR...should be a "clue" to investors regarding the respect and credence being shown to Brilacidin's potential as a "miracle drug" (anti-bacterial and antiviral)...as noted in the Military Symposium's Brilacidin SARS-CoV-2 Manuscript https://www.ipharminc.com/press-release/2021/8/2/innovation-pharmaceuticals-provides-update-on-brilacidin-antiviral-research

The continuation of UP/UPS trials (

The company's actively setting up Phase III of OM (Fast Track Designation), after successfully completed a Phase 2 trial of Brilacidin in Oral Mucositis, and aligning with the FDA on a planned Phase 3 program... IMO could come immediately on the heels of the successful Covid-19 trial results.

and that is not all...

and Innovation Pharma license agreement with Alfasigma S.p.A, granting the company exclusive rights to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) in Inflammatory Bowel Disease (IBD).

ALFASIGMA...would not be preparing $ multi- millions on Brilacidin...all on its dime (and payments of $24M and royalties) without a firm belief in Brilacidin's efficacy... IMO ... they should be ready to "rock and roll" upon confirmation of production and delivery of Brilacidin...

of course... least we also forget about the ongoing formulation development of Brilacidin for UC and being on the run-way for ABSSSI where ...

... "Brilacidin is being advanced in the clinic under Qualified Infectious Disease Product (QIDP) designation — qualifying the drug candidate for Fast Track and Priority Review, as well as an extra 5 years of market exclusivity upon drug approval. A Phase 2b trial was completed evaluating Brilacidin as an intravenously administered medication in treating Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Trial data showed a single dose of Brilacidin to be comparable in safety and efficacy to a 7-day dosing regimen of FDA-approved Daptomycin."

INVESTORS should not forget...BRILACIDIN HAS NEVER FAILED A CLINICAL TRIAL...AND...IT IS A FRANCHISE...for MULTIPLE INDICATIONS...

IMO...After DATA RELEASE...IPIX based upon BRIACIDIN alone...WILL BECOME A SERIOUS ACQUISITION/LICENSOR CANDIDATE FOR GILD, MERCK, AND TAKEDA...as well as a few others...

Meanwhile, IMO...$2.50 is the FIRST target in days of Data release...and as the FRANCHISE becomes known, 10X $2.50 not far behind...

PS. Better than " pro ball Pr firm, is ceo talking to squawk box"...IS DITCHING THE "Pro ball PR FIRM (a counterproductive move with the FDA) and "DEGRADO and KESSLER TALKING ON SQUAK BOX"...after he and Kessler first take Brilacidin to the top of every regulatory agency...for first EUA, then "full approval"... IMO (and speculation) its coming in that order.

PSS...just back and well-rested vacation...saw DJT last night...he looks great and 2024 is in his scope.